Opinion: Exploitation in the name of biomedical innovation cannot be tolerated

There are no shortcuts in science. Intellectual honesty and multiple levels of review are necessary before a product, especially one that promises a treatment for desperate patients, can be approved.

Biogen’s announcement on Tuesday that it is “substantially eliminating” its spending on Aduhelm caps a remarkable story of drug development gone bad.

In a controversial move in June 2021, the Food and Drug Administration approved the Alzheimer’s drug, disregarding the strong objections of a panel of independent experts that said the science didn’t support approving the drug.

Read the rest…